The treatment of human SH-SY5Y cells with exenatide has been shown to increase the numbers of neurite-bearing cells, in addition to the actual number of neurites per cell
PMID: 28228426
Globally, these observations encourage further studies exploring gender differences in obesity and individualization of obesity pharmacotherapy to optimize the potential benefits of novel anti-obesity drugs in different medical contexts
Given this close relationship, scientists have hoped that semaglutide and similar drugs that mimic the hormone GLP-1 (already approved to treat obesity and diabetes) could be an effective treatment for MASLD/MASH as well
The proposal is straightforward: Move toward biomarker-driven patient stratification Design more flexible, biology-informed clinical trials Align regulatory approaches with what already works in oncology and dementia Dementia offers a useful reference point
In addition to cosmetic goals, wellness-focused patients, anti-aging candidates, and individuals seeking detox support may also benefit from glutathione therapy
